These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12543142)

  • 1. Transmission-blocking vaccine of vivax malaria.
    Tsuboi T; Tachibana M; Kaneko O; Torii M
    Parasitol Int; 2003 Mar; 52(1):1-11. PubMed ID: 12543142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates.
    Tsuboi T; Kaslow DC; Gozar MM; Tachibana M; Cao YM; Torii M
    Mol Med; 1998 Dec; 4(12):772-82. PubMed ID: 9990863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates.
    Sattabongkot J; Tsuboi T; Hisaeda H; Tachibana M; Suwanabun N; Rungruang T; Cao YM; Stowers AW; Sirichaisinthop J; Coleman RE; Torii M
    Am J Trop Med Hyg; 2003 Nov; 69(5):536-41. PubMed ID: 14695092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes.
    Hisaeda H; Stowers AW; Tsuboi T; Collins WE; Sattabongkot JS; Suwanabun N; Torii M; Kaslow DC
    Infect Immun; 2000 Dec; 68(12):6618-23. PubMed ID: 11083773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic diversity and natural selection of transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 in Plasmodium vivax Myanmar isolates.
    Lê HG; Kang JM; Jun H; Lee J; Moe M; Thái TL; Lin K; Myint MK; Yoo WG; Sohn WM; Kim TS; Na BK
    Acta Trop; 2019 Oct; 198():105104. PubMed ID: 31336059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy.
    Kongkasuriyachai D; Bartels-Andrews L; Stowers A; Collins WE; Sullivan J; Sattabongkot J; Torii M; Tsuboi T; Kumar N
    Vaccine; 2004 Aug; 22(23-24):3205-13. PubMed ID: 15297075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism.
    Hisaeda H; Collins WE; Saul A; Stowers AW
    Vaccine; 2001 Dec; 20(5-6):763-70. PubMed ID: 11738740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic diversity of transmission blocking vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax clinical isolates from Iran.
    Zakeri S; Razavi S; Djadid ND
    Acta Trop; 2009 Mar; 109(3):176-80. PubMed ID: 18950597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic diversity of transmission-blocking vaccine candidates Pvs25 and Pvs28 in Plasmodium vivax isolates from Yunnan Province, China.
    Feng H; Zheng L; Zhu X; Wang G; Pan Y; Li Y; Yang Y; Lin Y; Cui L; Cao Y
    Parasit Vectors; 2011 Nov; 4():224. PubMed ID: 22117620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
    Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
    Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
    Wu Y; Ellis RD; Shaffer D; Fontes E; Malkin EM; Mahanty S; Fay MP; Narum D; Rausch K; Miles AP; Aebig J; Orcutt A; Muratova O; Song G; Lambert L; Zhu D; Miura K; Long C; Saul A; Miller LH; Durbin AP
    PLoS One; 2008 Jul; 3(7):e2636. PubMed ID: 18612426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization.
    Tachibana M; Suwanabun N; Kaneko O; Iriko H; Otsuki H; Sattabongkot J; Kaneko A; Herrera S; Torii M; Tsuboi T
    Vaccine; 2015 Apr; 33(16):1901-8. PubMed ID: 25765968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigenic repertoire of Plasmodium vivax transmission-blocking vaccine candidates from the Indian subcontinent.
    Prajapati SK; Joshi H; Dua VK
    Malar J; 2011 May; 10():111. PubMed ID: 21535892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapid genotyping method for the vivax malaria transmission-blocking vaccine candidates, Pvs25 and Pvs28.
    Tsuboi T; Kaneko O; Cao YM; Tachibana M; Yoshihiro Y; Nagao T; Kanbara H; Torii M
    Parasitol Int; 2004 Sep; 53(3):211-6. PubMed ID: 15468527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate.
    Tachibana M; Sato C; Otsuki H; Sattabongkot J; Kaneko O; Torii M; Tsuboi T
    Vaccine; 2012 Feb; 30(10):1807-12. PubMed ID: 22245309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission.
    Blagborough AM; Yoshida S; Sattabongkot J; Tsuboi T; Sinden RE
    Vaccine; 2010 Aug; 28(37):6014-20. PubMed ID: 20637303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein.
    Arévalo-Herrera M; Solarte Y; Yasnot MF; Castellanos A; Rincón A; Saul A; Mu J; Long C; Miller L; Herrera S
    Am J Trop Med Hyg; 2005 Nov; 73(5 Suppl):32-7. PubMed ID: 16291764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence variation of ookinete surface proteins Pvs25 and Pvs28 of Plasmodium vivax isolates from Southern Mexico and their association to local anophelines infectivity.
    González-Cerón L; Alvarado-Delgado A; Martínez-Barnetche J; Rodríguez MH; Ovilla-Muñoz M; Pérez F; Hernandez-Avila JE; Sandoval MA; Rodríguez Mdel C; Villarreal-Treviño C
    Infect Genet Evol; 2010 Jul; 10(5):645-54. PubMed ID: 20363376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms of Plasmodium vivax ookinete (sexual stage) surface proteins (Pvs25 and Pvs28) from Thailand.
    Kuesap J; Suphakhonchuwong N; Rungsihirunrat K
    Infect Genet Evol; 2024 Mar; 118():105558. PubMed ID: 38244749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of the Transmission-Blocking Vaccine Candidates Pvs28 and Pvs25 in Plasmodium vivax: Geographic Differentiation and Evidence of Positive Selection.
    Chaurio RA; Pacheco MA; Cornejo OE; Durrego E; Stanley CE; Castillo AI; Herrera S; Escalante AA
    PLoS Negl Trop Dis; 2016 Jun; 10(6):e0004786. PubMed ID: 27347876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.